← Back

Guangdong Biolight Meditech Co Ltd

Guangdong Biolight Meditech Co., Ltd. engages in the research and development, production, sale, and service of medical devices products and solutions in China. It operates in two segments, Life Information and Support, and Kidney Disease. The company offers emergency and critical care monitor, subcritical care monitor, general ward monitor, outpatient monitor, neonatal monitor, infusion pump, electrocardiograph, maternal and fetal monitor, defibrillator, multifunctional suspension device, internet of things, and central station; hemodiafiltration equipment, peritoneal dialysis equipment, liquid supply system, and hemodialysis water equipment; and finger clip oximeter, sphygmomanometer, fetal heart rate monitor, body temperature monitoring system, and home medical mall, as well as hemoperfusion devices, high throughput and low flu hemodialyzer, hemodialysis concentrate, dry powder, citric acid disinfectant, tube/puncture needle, dialysate filter, and dialysis fluid filter. It offers its products under JUNKANG MEDICAL, BIOLIGHT HEALTHCARE, TRUSTRONG, BR Medical Service, SHENBA, HUA VUE MEDICAL, BOAO TIANSHENG, and other brand names. The company serves medical institutions through direct sales channel. It also exports its products. The company was founded in 1993 and is headquartered in Zhuhai, China.

Price · split & dividend adjusted
News & notes moving 300246.CS
300246.CS▼

Biolight's 2026 interim report shows net loss of 34.49 million yuan

Biolight released its 2026 interim report, with net profit attributable to the parent company at negative 34.49 million yuan, swinging from profit to loss. The company's total operating revenue was 518 million yuan, down 1.09% year-on-year. Net cash inflow from operating activities was 67.12 million yuan, the asset-liability ratio rose to 52.11%, gross margin fell to 22.86%, and ROE was negative 3.13%.
300246.CS ▼
Jiemian·3dRead more ▾
300246.CS

Biolight terminates control change and co-opts two directors including the founder of Weigu Information

Biolight announced the termination of its planned control change, but the company's capital operations are still moving forward. On the evening of August 9, Biolight disclosed the termination of the control change. At the same time, the board received written resignation reports from Zhang Daoguo and Xu Wei. After resigning as non-independent directors, the two will continue to serve as vice president and general manager of the active manufacturing system, and chief financial officer and general manager of the finance system, respectively. The company plans to nominate Wu Jia and Liu Jia as non-independent directors of the ninth board. Both were born in 1982 and are respectively the founder, chairman and president, and co-founder and vice president of Weigu Information Technology Quzhou Company. In January this year, Biolight's actual controllers Yan Jinyuan and Wang Shi signed a share transfer agreement with Zhejiang Quwei Zhihe Holding Partnership, transferring 18.5206 million shares at 9.45 yuan per share, representing 7 percent of total share capital, for a total transaction price of about 175 million yuan. After the transfer was completed in May, Quwei Zhihe became the second-largest shareholder, with Wu Jia serving as its executive partner. On June 29, Biolight established Zhuhai Weibao Technology, in which the listed company holds 51 percent. Its business scope covers integrated circuit chip and product sales, design and services, extending the company's reach from medical devices into the semiconductor sector.
300246.CS
证券时报·12dRead more ▾
Brain-Computer Interface▲

Zhejiang Issues Brain-Computer Interface Measures, Biolight Surges by 20% in Afternoon Trading

The medical device sector rebounded in afternoon trading, with Biolight hitting the 20% daily limit up. Earlier, Chaoyan Medical rose by the daily limit, Aohua Endoscopy gained over 10%, and Apon Medical, Rendu Biotechnology, Haitex, Nanwei Medical, and Lude Medical also followed the upward trend. The General Office of the Zhejiang Provincial People's Government issued several measures this morning to promote industry-academia-research collaboration in brain-computer interfaces, aiming for future industry revenue from brain-computer interfaces to exceed 5 billion yuan by 2027, and to establish a globally competitive hub for brain-computer interface technology and industry innovation by 2030.
300246.CS ▲688193.CG ▲688212.CG ▲300753.CS ▲
Brain-Computer Interface ▲
上海证券报·14dRead more ▾
300246.CS▼

Biolight Resumes Trading with Limit-Down, Control Change Plan Terminated

Biolight resumed trading on August 10 and immediately hit its daily limit down, closing at 15.41 yuan per share, down 19.99 percent, with a total market value of 4.078 billion yuan. Before the suspension, the company had announced that its controlling shareholder was planning a major event that could lead to a change of control. However, on the evening of the 9th, it announced that due to the many issues involved, the relevant transaction parties decided to terminate the planning, and trading in the stock and convertible bonds resumed. The company stated that its operations are currently normal and that the termination will not have a material adverse impact on its performance or financial condition. Biolight has been suffering continuous losses in recent years, with net profit attributable to the parent company of minus 65.1851 million yuan, minus 71.4413 million yuan, and minus 69.4278 million yuan from 2023 to 2025, accumulating losses of over 200 million yuan over the three years.
300246.CS ▼
行情信息·16dRead more ▾
300246.CS▲

Talkweb Information System First-Half Net Profit Falls 12.16% Year-on-Year

Talkweb Information System released its 2026 semi-annual report, achieving operating revenue of 1.312 billion yuan, up 0.39% year-on-year, with net profit attributable to shareholders of the listed company at 69.222 million yuan, down 12.16% year-on-year. The company plans to distribute a cash dividend of 0.25 yuan for every 10 shares to all shareholders. As of the end of the reporting period, the company had over 30 products certified through OpenHarmony compatibility assessment, with related products in the market expansion and application stage. In other news, WuXi AppTec announced that a U.S. court has granted its preliminary injunction motion, shielding the company from immediate adverse impact while it challenges the U.S. Department of Defense's 1260H designation in judicial proceedings. Gaozheng Explosives' controlling shareholder is set to change to Tibet Geology and Mineral Resources Group. Ningxia Building Materials plans to repurchase shares worth 100 million to 200 million yuan for cancellation. Wuhan P&S Information Technology saw semi-annual net profit surge 209.5% year-on-year. Galaxy Microelectronics' semi-annual net profit rose 77.28% year-on-year. Hongte Technology plans to raise no more than 650 million yuan through a rights issue for its Thailand base and other projects. Tuoxin Pharmaceutical plans to raise no more than 228 million yuan through a private placement of shares. Biolight has terminated the planned change of control, and its shares and convertible bonds will resume trading on August 10. Huadong Medicine's wholly-owned subsidiary obtained EU MDR CE certification for its medical aesthetics product. Jumpcan Pharmaceutical's subsidiary obtained drug registration certificates for pediatric laxative granules and mesalazine sustained-release granules. Chinese Health's wholly-owned subsidiary had its drug registration application for ferrous succinate tablets accepted.
002261.CS ▼002827.CS ▲300176.CS ▲300184.CS ▲300246.CS ▲600449.CG ▲+4
CLS·17dRead more ▾
300246.CS▼2

Biolight Terminates Control Change Plan, Trading Resumes Tomorrow

Biolight announced the termination of its planned control change, and trading in the company's shares and convertible bonds will resume from the market open on August 10. During the suspension, the controlling shareholder and the counterparty fully discussed the relevant major matters, but due to the many issues involved, all parties decided to terminate the plan after careful consideration. Previously, the company's actual controller Yan Jinyuan and concert party Wang Shi had agreed to transfer a 7% stake to Quwei Zhihe in January this year, with a total transaction value of approximately 175 million yuan. After the transfer, the two together hold 22.18% of the shares. Biolight has reported losses for three consecutive years, with net profit attributable to the parent company of minus 65.19 million yuan in 2023, minus 71.44 million yuan in 2024, and minus 69.43 million yuan in 2025. In the first quarter of this year, it continued to lose 7.32 million yuan. The company also recently adjusted its 2022 private placement fundraising projects, and it is expected that the remaining raised funds of approximately 60.66 million yuan will be permanently used to supplement working capital.
300246.CS ▼
中国基金报·17dRead more ▾
300246.CS5

Biolight Plans Ownership Change; Stock and Convertible Bonds to Halt Trading Next Monday

Biolight announced that its controlling shareholder is planning a change of control. Trading in the company's stock and convertible bonds will be suspended starting August 3, with the halt expected to last no more than two trading days. The convertible bonds, known as Biolight Convertible Bonds, will also suspend conversion into shares.
300246.CS
证券时报·26dRead more ▾
300246.CS

Biolight controlling shareholder plans change of control; stock surges 10.37% before suspension

Biolight controlling shareholder Yan Jinyuan is planning a change of control. Trading in the company's shares and convertible bonds has been suspended since the market opened on August 3, with the suspension expected to last no more than two trading days. On the last trading day before the suspension, Biolight's stock price closed at 19.26 yuan per share, up 10.37%, giving it a total market value of 5.096 billion yuan. In January this year, Yan Jinyuan and his wife Wang Shi transferred a combined 18.5206 million Biolight shares, representing 7% of the company's total share capital, to Zhejiang Quwei Zhihe Holding Partnership at a price of 9.45 yuan per share through a negotiated transfer. The transaction was completed on May 28, making Quwei Zhihe the second-largest shareholder of Biolight. Biolight has been reporting losses in recent years, with net profit attributable to the parent company of minus 65.1851 million yuan in 2023, minus 71.4413 million yuan in 2024, and minus 69.4278 million yuan in 2025. In the first quarter of 2026, net profit attributable to the parent company was minus 7.3189 million yuan, a year-on-year decline of 150.66%.
300246.CS
宝莱特2026年一季报·26dRead more ▾
300246.CS▲2

Biolight Blood Purification Devices Receive Medical Device Registration Certificates

Biolight has obtained Medical Device Registration Certificates issued by the National Medical Products Administration for its blood purification devices Elix-Ω and Elix-90. These are Class III medical devices indicated for various blood purification therapies in adult patients, with registration valid until July 15, 2031. In the first quarter of 2026, Biolight recorded revenue of 243 million yuan and a net loss attributable to the parent company of 7.32 million yuan.
300246.CS ▲
财中社·35dRead more ▾
© 2026 MarketDXAsset